Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies.
Frank S, Persse T, Coleman I, Bankhead A 3rd, Li D, De-Sarkar N, Wilson D, Rudoy D, Vashisth M, Galipeau P, Yang M, Hanratty B, Dumpit R, Morrissey C, Corey E, Montgomery RB, Haffner MC, Pritchard C, Vasioukhin V, Ha G, Nelson PS.
Frank S, et al. Among authors: vasioukhin v.
bioRxiv [Preprint]. 2024 Jul 19:2024.07.16.603734. doi: 10.1101/2024.07.16.603734.
bioRxiv. 2024.
PMID: 39071291
Free PMC article.
Preprint.